Novavax shares hit a one-year high driven by optimism over its Sanofi partnership for a flu-COVID combo shot. The company reported a 67% revenue jump in Q4 to $147 million. Novavax is pivoting to a partnership-led model, moving away from standalone COVID vaccines to focus on long-term growth with its Matrix-M technology.